Antibody to oxidized low-density lipoprotein and cardiovascular mortality in end-stage renal disease

✍ Scribed by Shoji, Tetsuo; Fukumoto, Mariko; Kimoto, Eiji; Shinohara, Kayo; Emoto, Masanori; Tahara, Hideki; Koyama, Hidenori; Ishimura, Eiji; Nakatani, Tatsuya; Miki, Takami; Tsujimoto, Yoshihiro; Tabata, Tsutomu; Nishizawa, Yoshiki

• Publisher: Nature Publishing Group
• Year: 2002
• Tongue: English
• Weight: 135 KB
• Volume: 62
• Category: Article
• ISSN: 0085-2538
• DOI: 10.1046/j.1523-1755.2002.00692.x

✦ Synopsis

Background:

Immune response to oxidized low-density lipoprotein (oxldl) may modulate the process of atherogenesis and cardiovascular disease.

Methods:

We performed a prospective, observational cohort study in 249 patients with end-stage renal disease (esrd) to examine whether the serum titer of anti-oxldl antibody can predict cardiovascular mortality.

Results:

The median anti-oxldl antibody titer was 320 mu/ml at baseline. during the follow-up (63 +/- 23 months), 72 deaths including 34 cardiovascular deaths occurred. when the subjects were divided into two groups by the median titer, the high titer group showed a lower risk for cardiovascular mortality (p = 0.040 by kaplan-meier analysis and log-rank test). multivariate cox proportional hazards model indicated that the lower risk of cardiovascular death in the high titer group remained significant (hazard ratio of 0.46, 95%ci 0.23-0.95, p = 0.037) and independent of age, presence of vascular complications, presence of diabetes mellitus, and elevated c-reactive protein. in contrast, anti-oxldl antibody titer was not associated with non-cardiovascular mortality.

Conclusions:

These results demonstrate, to our knowledge for the first time, that serum anti-oxldl antibody titer is an independent predictor of cardiovascular mortality in a cohort of patients with esrd.